

Rotation Report Sample
Version 2

Due Date: August 9, 1998

Analysis of the Guanine Nucleotide Exchange Activity
of the
S. cerevisiae Ats1 Protein

Anita H. Corbett

Advisor: Amy Jones
Rotation 1

Abstract: The goal of my rotation project was to express, purify, and examine the exchange activity of a putative guanine nucleotide exchange factor, Ats1p. The *S. cerevisiae* *ATS1* gene encodes a protein with homology to the guanine nucleotide exchange factor for Ran, Prp20p. My approach was to use an established purification protocol and exchange assay to determine whether Ats1p, like Prp20p, acts as a nucleotide exchange factor for Ran. Both the Ats1 protein and the control exchange factor Prp20p have been expressed and purified and are ready to be tested in an established activity assay.

All macromolecules that move into and out of the nucleus transit the nuclear envelope via large proteinaceous complexes termed nuclear pores (1). These nuclear pore complexes essentially serve as channels that perforate the double membrane that surrounds the nucleus. Transport substrates do not, however, flow freely back and forth through the nuclear pores. The traffic through these channels is meticulously regulated by a number of soluble factors that are required for both import and export of substrates from the nucleus (2). The most central of these soluble factors is the small GTP-binding protein Ran which is required for virtually all substrates to traverse the nuclear pore (3).

As with other cellular G-proteins, Ran cycles between a GTP-bound and a GDP-bound state. The rate of GTP hydrolysis by isolated Ran protein is extremely slow (4). In the cell, several accessory factors enhance the rate at which Ran cycles between the two nucleotide-bound states. The GTPase activating protein (GAP) for Ran is the Rna1 protein which stimulates the rate at which Ran hydrolyzes GTP to GDP (5). The guanine nucleotide exchange factor (EF) for Ran is the Prp20 protein which stimulates the release of GDP from Ran (6). The concerted action of these two Ran regulatory proteins allows Ran to cycle rapidly between the GTP- and the GDP-bound states.

Many current models for how directional transport of substrates into and out of the nucleus is achieved rely heavily on the absolute cellular compartmentalization of the Ran GAP and EF (7). While Ran is located throughout the cell (8), the GAP is primarily confined to the cytoplasm (9) and the EF is confined to the nucleus (10). The localization of these proteins suggests that Ran is mostly in the GDP-bound state when it is in the cytoplasm due to the action of the GAP. In contrast, logic would dictate that Ran should be mostly in the GTP-bound state within the nucleus due to the activity of the EF. This distribution of Ran-GTP and Ran-GDP melds nicely with a directional model in which Ran-GDP initiates import of proteins into the nucleus and Ran-GTP causes the release of these proteins to the nuclear interior. This model has never been directly tested because it is difficult to determine what the nucleotide-bound state of Ran is *in vivo* in any specific cellular compartment.

Obviously the model described above is dependent on the presence of only the defined Ran regulators, Rna1p and Prp20p. However, the complete sequencing of the *S. cerevisiae* genome has revealed that there are at least two yeast genes that encode proteins with significant homology to Prp20p. One of these genes, *ATS1*, was identified several years ago as an alpha-tubulin mutant suppressor (11) although subsequent experiments have not revealed any direct connection to alpha-tubulin. The goal of

this work was to use a biochemical approach to determine whether the Ats1 protein might serve as a guanine nucleotide exchange factor for Ran.

Methods and Results

The Ats1 protein was expressed with an N-terminal 6-His tag. In the past, the Corbett laboratory has used a 6-His tagged version of the Prp20 protein and found that the tag does not interfere with the exchange activity. The expression plasmid for Ats1p was generated by amplifying the *ATS1* coding region by PCR with Vent polymerase (New England Biolabs) using oligos AC135 and 136 engineered with a 5'-*Bam*HI site and a 3'-*Hind*III site, respectively. The template used for the PCR was the plasmid pAC214 which contains the genomic *ATS1* clone. The resulting PCR product which was the expected 1.1 kb in length was digested with *Bam*HI and *Hind*III and cloned into the expression plasmid pET15b to generate pAC341 (Figure 1). Cloning was confirmed initially by miniprepping and finally by sequencing the entire open-reading frame of the *ATS1* gene including the N-terminal 6-His tag. For control exchange experiments the Prp20p protein was expressed from the existing expression construct pAC215. Purified Ran protein was already available in the laboratory.




Figure 1. Schematic of Ats1p expression plasmid.

Both the pAC341 (Ats1p) and the pAC215 (Prp20p) expression plasmids were transformed into BL21 (DE3) cells. Two transformants were chosen for each protein. These transformants were inoculated into 2 ml overnight cultures of Luria Broth containing 100 µg/ml ampicillin (LB-AMP) and grown to saturation. In the morning, the overnight cultures (2 ml) were inoculated into separate 500 ml cultures of LB-AMP. These cultures were grown at 30°C with shaking until they reached an OD600 of 0.375. Cultures were then induced with .5 mM isopropylthio- β -D-galactoside (IPTG). One ml samples of the cultures were collected just prior to the addition of IPTG and then at one hour intervals until a three hour induction was completed. Following the three hour induction, the *E. coli* were pelleted by centrifugation at 6000Xg for 15 min at 4°C. Pellets were then stored at -20°C until needed.

Both the pAC341 (Ats1p) and the pAC215 (Prp20p) expression plasmids were transformed into BL21 (DE3) cells. Two transformants were chosen for each protein. These transformants were inoculated into 2 ml overnight cultures of Luria Broth containing 100 µg/ml ampicillin (LB-AMP) and grown to saturation. In the morning, the overnight cultures (2 ml) were inoculated into separate 500 ml cultures of LB-AMP. These cultures were grown at 30°C with shaking until they reached an OD600 of 0.375. Cultures were then induced with .5 mM isopropylthio- β -D-galactoside (IPTG). One ml samples of the cultures were collected just prior to the addition of IPTG and then at one hour intervals until a three hour induction was completed. Following the three hour induction, the *E. coli* were pelleted by centrifugation at 6000Xg for 15 min at 4°C. Pellets were then stored at -20°C until needed.

To assay protein expression in the induced *E. coli*, the one ml samples were analyzed by SDS-PAGE (12) to determine whether a band of the appropriate size was induced. Each of the one ml samples was pelleted in a microcentrifuge and then resuspended in 50 µl (no induction), 100 µl (1h induction), 150 µl (2h induction), and 200 µl (3h induction) of protein sample buffer (50 mM Tris-HCl, 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue, 10% glycerol, pH 6.8) to compensate for the increase in cell number during the logarithmic growth of the culture. Cell pellets were lysed by boiling at 100°C for 10 min in sample buffer. Samples (10µl/lane) were then loaded onto a 10% polyacrylamide gel. Following electrophoresis, proteins were visualized by staining with coomassie brilliant blue. As shown in Figure 2 both of the Prp20p samples induced a band corresponding to the expected size of 6-

His-tagged Prp20p (~47 kDa) following a three hour induction. In the case of the Ats1p samples only one culture induced a band of ~38 kDa that corresponds to the expected size of 6-His-tagged Ats1p.

Immunoblotting was used to confirm that the bands observed correspond to the Prp20 and Ats1 proteins. A commercially available anti-His antibody (Qiagen) was used to blot samples that were resolved by SDS-PAGE and transferred to nitrocellulose by standard methods (13). Bands corresponding to the predicted




Figure 3. Detection of induced proteins by anti-His Antibodies.
 Lane 1, no induction;
 Lanes 2 & 3, Prp20p 3h induction;
 Lanes 4 & 5, Ats1p 3 h induction.

observed correspond to the Prp20 and Ats1 proteins. A commercially available anti-His antibody (Qiagen) was used to blot samples that were resolved by SDS-PAGE and transferred to nitrocellulose by standard methods (13). Bands corresponding to the predicted

size for both 6 His-Prp20p and 6-His-Ats1p are recognized by the anti-His antibody (Figure 3).

The protocol for purification of the 6-His tagged proteins was essentially as described in for the Invitrogen X-press system protein purification protocol. This protocol has been used successfully by the Corbett laboratory in the past to express functional 6-His-tagged Prp20p.

Pellets corresponding to the expressed Prp20p and Ats1p were resuspended in 10 ml native binding buffer (20 mM NaPO₄, pH 7.8, 500 mM NaCl). Cells pellets were lysed by five 30 s pulses with a Biosystems microprobe sonicator. Soluble and insoluble fractions were separated by centrifugation at 6000Xg (5000 RPM in the GSA rotor) for 15 min at 4°C. The supernatant was then poured into a new bottle and recentrifuged to remove any particulate matter. This soluble fraction was then analyzed as described above for the presence of the recombinant Prp20p and Ats1p. Previous experiments in the laboratory suggested that both proteins were soluble under these conditions and this was confirmed (See Figure 4).

In order to purify the tagged proteins, the soluble fractions from both proteins were bound in batch to 1 ml Ni-NTA agarose (Qiagen) that had been pre-equilibrated in native binding buffer. Binding was carried out in a 15 ml conical tube at 4°C for one hour. The matrix was then pelleted by a 5 min spin at 1000Xg. Non-specific proteins bound were removed by three 10 ml washes with wash buffer (20 mM NaPO₄, pH 6.0, 500 mM NaCl). These washes were followed by a single wash with stringent wash buffer (20 mM NaPO₄, pH 5.5, 500 mM NaCl). Samples were then eluted by incubation with 2 times 2 ml of elution buffer for 10 min each (20 mM NaPO₄, pH 4.0, 500 mM NaCl). These samples were pooled and concentrated with Centriprep-30 (Amicon, Inc.). Final protein concentrations were determined using the Bio-Rad




Figure 2. Induction of Prp20p and Ats1p. Lane 1, no induction;
 Lanes 2 & 3, Prp20p 3h induction;
 Lanes 4 & 5, Ats1p 3 h induction.




Figure 4. Silver stained gel of purified proteins. Lane 1, uninduced lysate; Lane 2, induced Prp20p lysate soluble fraction; Lane 3, purified 6-His-Prp20p; Lane 4, induced Ats1p lysate soluble fraction; Lane 5, purified 6-His-Ats1p

protein assay using purified BSA as a standard. Purity was also assessed by analyzing the final concentrated samples by SDS-PAGE followed by silver staining (Figure 4).

Discussion

The Ats1 protein shares structural motifs termed RCC1 signature sequences with the known nucleotide exchange factor for Ran, Prp20p (11). The goal of the proposed experiments was to determine whether Ats1p, like Prp20p, can serve as a nucleotide exchange factor for Ran. These experiments have important implications for determining whether RCC1 signature sequences suggest a specific interaction with Ran or another G-protein. The only two RCC1 signature containing proteins that have ever been biochemically characterized are the mammalian nucleotide exchange factor for Ran, RCC1, and the *S. cerevisiae* homologue, Prp20p. No function has been ascribed to any other protein that contains these motifs. The outcome of these experiments might indicate whether these motifs are specific for interactions with Ran or whether they merely implicate a protein in an interaction with a GTP-binding protein. Finally, it is also possible that these motifs are unrelated to the exchange activity and are indicative of some other unidentified protein function. The latter hypothesis seems somewhat unlikely as the crystal structure of the human RCC1 protein was recently solved and the structural analysis revealed that the seven RCC1 motifs in the RCC1 protein form the basis for the overall protein fold (14).

The purified expressed proteins are now available for carrying out an assay for nucleotide exchange on Ran. The experiment will be conducted in the following manner which is essentially as described by Bischoff and Ponstingl (6). Purified Ran protein will be incubated with [³H]GDP. This charged Ran will then be incubated with various amounts of either buffer, Prp20p, or Ats1p over a time course in the presence of excess unlabeled GTP. The amount of exchange that occurs will be quantitated by a filter binding assay. At each time point a portion of the reaction will be vacuum filtered through a 0.45 μm nitrocellulose filter. Protein will bind to the filter while free nucleotide will pass through. Thus, any protein associated radioactivity will remain bound to the filter and can be quantitated by scintillation counting. Rates of exchange will be determined by plotting time vs $\ln(C_t/C_0)$ where C_t = number of counts at any particular time point and C_0 = number of counts at time zero.

Three outcomes are possible for the exchange assay: **1)** Ats1p may not stimulate nucleotide exchange on Ran; **2)** it may stimulate as well or better than Prp20p (~10⁵-fold); or **3)** it may stimulate the exchange activity but not as well as Prp20p. If Ats1p does not stimulate guanine nucleotide exchange on Ran this might suggest either that Ats1p is not an exchange factor or that it is specific for some G-protein other than Ran. If this is the outcome of the assay, it will also be necessary to consider the possibility that the recombinant epitope-tagged Ats1 protein is not functional. This is currently extremely difficult to test as there are no activities yet known for Ats1p. If Ats1p is comparable to Prp20p at stimulating exchange on Ran, it will be necessary to carry out *in vivo* experiments to determine whether Ats1p does act on Ran *in vivo*. Finally, if Ats1p has an intermediate ability to enhance the exchange rate on Ran, this could suggest that Ats1p is indeed an exchange factor for a G-protein but perhaps Ran is not its *in vivo*

target. Alternatively, it would again be necessary to consider the fact that the assays are being carried out with a recombinant protein that may not retain its full functionality. Regardless of the results, these experiments should lend insight into the function of Ats1p.

As a complement to this biochemical approach future experiments in the Corbett laboratory will use a genetic approach to characterize the *in vivo* role of Ats1p. The laboratory has generated a deletion strain that lacks the *ATSI* gene and this strain will be used as the basis for a synthetic lethal screen. The combination of these genetic and biochemical approaches should ultimately identify an *in vivo* role for Ats1p.

References

1. M. P. Rout, S. R. Went, *Trends Cell Biol.* **4**, 357-365 (1994).
2. A. H. Corbett, P. A. Silver, *Microbiol. Mol. Biol. Revs.* **61**, 193-211 (1997).
3. M. S. Moore, G. Blobel, *Trends Biol. Sci.* **19**, 211-216 (1994).
4. C. Klebe, T. Nishimoto, F. Wittinghofer, *Biochemistry* **32**, 11923-11928 (1993).
5. A. H. Corbett, et al., *J. Cell Biol.* **130**, 1017-1026 (1995).
6. F. R. Bischoff, H. Ponstingl, *Nature* **354**, 80-82 (1991).
7. D. M. Koepp, P. A. Silver, *Cell* **87**, 1-4 (1996).
8. P. Belhumeur, et al., *Mol. Cell. Biol.* **13**, 2152-2161 (1993).
9. A. K. Hopper, H. M. Traglia, R. W. Dunst, *J. Cell Biol.* **111**, 309-321 (1990).
10. M. Fleischmann, et al., *Mol. Gen. Genet.* **227**, 417-423 (1991).
11. D. Kirkpatrick, F. Solomon, *Genetics* **137**, 381-392 (1994).
12. U. K. Laemmli, *Nature* **227**, 680-685 (1970).
13. H. Towbin, T. Staehelin, J. Gordon, *Proc. Natl. Acad. Sci. USA* **76**, 4350-4354 (1979).
14. L. Renault, et al., *Nature* **392**, 97-101 (1998).